miR-29b binding site in human progranulin mRNA 3′ UTR (GRN 3′ UTR miR-29b binding site)

The miR-29b binding site in the human progranulin (GRN) mRNA 3′ untranslated region (UTR) is a critical regulatory sequence that controls the post-transcriptional expression of the progranulin protein. Progranulin is a secreted glycoprotein essential for lysosomal health, neuronal survival, and the modulation of inflammation; its haploinsufficiency due to GRN gene mutations is a major genetic cause of frontotemporal dementia (FTD) (Chen-Plotkin et al., 2010, PMID: 20159444). MicroRNA-29b (miR-29b) naturally binds to this specific site in the GRN mRNA, leading to reduced translation and lower progranulin levels, a process that is often exacerbated in neurodegenerative states (Jiachen Chen et al., 2014, PMID: 24501214). Therapeutic intervention involves using antisense oligonucleotides (ASOs) or target site blockers (TSBs) designed to bind specifically to this sequence. By sterically hindering the interaction between miR-29b and the GRN mRNA, these agents prevent microRNA-mediated silencing and effectively boost the production of endogenous progranulin. This strategy represents a precision medicine approach to restoring progranulin levels in the brain, potentially offering a disease-modifying treatment for patients with FTD and related tauopathies.

Other names

Progranulin 3′ UTR microRNA-29b target siteGRN 3′ UTR miR-29b binding elementPGRN 3′ UTR miR-29b site

Competitive inhibition of microRNA binding (Target Site Blockade) to prevent miR-29b-mediated translational repression and mRNA degradation, thereby increasing endogenous progranulin protein levels.